CVS Health (CVS) Upgraded to “Strong-Buy” at UBS Group

CVS Health (NYSE:CVS) was upgraded by equities researchers at UBS Group from an “outperform” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday, The Fly reports.

CVS has been the topic of several other research reports. Needham & Company LLC restated a “hold” rating on shares of CVS Health in a report on Sunday, September 10th. Oppenheimer reaffirmed a “buy” rating and issued a $95.00 price objective on shares of CVS Health in a research report on Monday, October 9th. Leerink Swann reaffirmed an “outperform” rating and issued a $85.00 price objective (down previously from $90.00) on shares of CVS Health in a research report on Tuesday, November 7th. SunTrust Banks set a $85.00 price objective on shares of CVS Health and gave the company a “buy” rating in a research report on Thursday, October 12th. Finally, Citigroup set a $76.00 price objective on shares of CVS Health and gave the company a “hold” rating in a research report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. CVS Health currently has a consensus rating of “Buy” and a consensus target price of $86.51.

CVS Health (CVS) opened at $73.20 on Thursday. The firm has a market cap of $74,475.17, a PE ratio of 15.12, a PEG ratio of 1.29 and a beta of 0.90. CVS Health has a 1-year low of $66.45 and a 1-year high of $84.72. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. During the same quarter last year, the firm posted $1.64 earnings per share. CVS Health’s revenue for the quarter was up 3.5% compared to the same quarter last year. research analysts anticipate that CVS Health will post 5.9 earnings per share for the current year.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the sale, the executive vice president now directly owns 15,556 shares in the company, valued at $1,166,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.61% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of CVS. Beacon Capital Management lifted its holdings in CVS Health by 1.7% in the 4th quarter. Beacon Capital Management now owns 366 shares of the pharmacy operator’s stock worth $36,000 after purchasing an additional 6 shares during the last quarter. Acrospire Investment Management LLC lifted its holdings in CVS Health by 542.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock worth $102,000 after purchasing an additional 900 shares during the last quarter. Fieldpoint Private Securities LLC lifted its holdings in CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares during the last quarter. Wealthcare Advisory Partners LLC lifted its holdings in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 991 shares during the last quarter. Finally, Arcadia Investment Management Corp MI lifted its holdings in CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares during the last quarter. Institutional investors and hedge funds own 81.63% of the company’s stock.

TRADEMARK VIOLATION WARNING: “CVS Health (CVS) Upgraded to “Strong-Buy” at UBS Group” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/04/cvs-health-cvs-upgraded-to-strong-buy-at-ubs-group.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

The Fly

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply